Kura Oncology’s Ziftomenib: Promising Potential in R/R AML Market with Favorable FDA Review and Strategic Growth

Bank of America Securities analyst Jason Zemansky has maintained their bullish stance on KURA stock, giving a Buy rating today.

Jason Zemansky’s rating is based on Kura Oncology’s promising potential in the competitive market for relapsed/refractory acute myeloid leukemia (R/R AML) with their menin inhibitor, ziftomenib. Despite initial concerns about data comparisons with Syndax’s revumenib and the emergence of QTc prolongation, Kura has demonstrated distinguishing features in efficacy, safety, and convenience that provide optimism for both near-term and long-term market competitiveness.
The recent acceptance of Kura’s New Drug Application (NDA) by the FDA for priority review further supports a favorable outlook, as it alleviates concerns about regulatory hurdles. Additionally, the company’s strategic commercial and development efforts, along with significant remaining milestones from partnerships, contribute to a compelling risk/reward profile, justifying the Buy rating and a price objective of $29.00.

In another report released today, Barclays also maintained a Buy rating on the stock with a $11.00 price target.

KURA’s price has also changed dramatically for the past six months – from $11.200 to $6.300, which is a -43.75% drop .